Yizhuo Zhao
Overview
Explore the profile of Yizhuo Zhao including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
957
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Li L, Jiang L, Wang Y, Zhao Y, Zhang X, Wu G, et al.
Clin Cancer Res
. 2019 Aug;
25(23):6967-6975.
PMID: 31413010
Purpose: Preclinical and retrospective studies suggested a role for metformin in sensitizing patients who have diabetes with non-small cell lung cancer (NSCLC) to EGFR tyrosine kinase inhibitors (TKIs). We therefore...
22.
Cui S, Ni Y, Zhao Y, Li Z, Xiong L, Liu J, et al.
Lung Cancer
. 2019 May;
132:45-53.
PMID: 31097093
Objectives: To establish a circulating tumor cell (CTC) enrichment system for non-small cell lung cancer (NSCLC) patients who received first-line treatment with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (EGFR-TKI),...
23.
Qiao R, Zhong R, Xu J, Zhang Y, Zhang B, Wang S, et al.
J Cardiothorac Surg
. 2019 Mar;
14(1):63.
PMID: 30925891
Background: The aim of this study was to determine the prognostic value of lymph node status in patients with pathologic N2 (pN2) stage IIIA small cell lung cancer (SCLC). Methods:...
24.
Wang J, Zhao Y, Wang Q, Zhang L, Shi J, Wang Z, et al.
Cancer Biol Med
. 2019 Feb;
15(4):443-451.
PMID: 30766754
Objective: Anlotinib hydrochloride is a multitarget tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor, fibroblast growth factor receptor, platelet-derived growth factor receptor, c-Kit, and c-MET; therefore, it exhibits...
25.
Han B, Li K, Wang Q, Zhang L, Shi J, Wang Z, et al.
JAMA Oncol
. 2018 Aug;
4(11):1569-1575.
PMID: 30098152
Importance: Anlotinib is a novel multitarget tyrosine kinase inhibitor for tumor angiogenesis and proliferative signaling. A phase 2 trial showed anlotinib to improve progression-free survival with a potential benefit of...
26.
Han B, Li K, Zhao Y, Li B, Cheng Y, Zhou J, et al.
Br J Cancer
. 2018 Feb;
118(5):654-661.
PMID: 29438373
Background: Anlotinib (AL3818) is a novel multitarget tyrosine kinase inhibitor, inhibiting tumour angiogenesis and proliferative signalling. The objective of this study was to assess the safety and efficacy of third-line...
27.
Cui S, Ye L, Wang H, Chu T, Zhao Y, Gu A, et al.
Clin Lung Cancer
. 2018 Jan;
19(3):e313-e322.
PMID: 29329944
Background: The SuperARMS EGFR Mutation Detection Kit (SuperARMS) is highly selective and sensitive and able to detect 41 of the most common somatic mutations in exons 18 to 21 of...
28.
Xiong L, Cui S, Ding J, Sun Y, Zhang L, Zhao Y, et al.
Oncotarget
. 2017 Oct;
8(38):63846-63856.
PMID: 28969034
Objectives: Genomic profiling using plasma cell-free DNA (cfDNA) represents a non-invasive alternative to tumor re-biopsy, which is challenging in clinical practice. The feasibility of dynamically monitoring epidermal growth factor receptor...
29.
Dong H, Cui S, Pan F, Dong L, Niu Y, Zhao Y, et al.
Zhongguo Fei Ai Za Zhi
. 2017 Feb;
20(2):114-123.
PMID: 28228223
Background: A survival analysis and the influencing factors for non-small cell lung cancer (NSCLC) patients with brain metastases accepting first-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKIs) treatment have...
30.
Cui S, Zhang W, Xiong L, Pan F, Niu Y, Chu T, et al.
Oncotarget
. 2016 Dec;
8(2):2771-2780.
PMID: 27926526
Capture-based next-generation sequencing (NGS) is a potentially useful diagnostic method to measure tumor tissue DNA in blood as it can identify concordant mutations between cell-free DNA (cfDNA) and primary tumor...